Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Neoplasms 14Colorectal Neoplasms 14Melanoma 12Carcinoma, Renal Cell 11Neoplasm Metastasis 9Solid Tumors 8Carcinoma, Hepatocellular 8Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Lung Neoplasms 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Lymphoma 5Kidney Neoplasms 4Endometrial Neoplasms 4Solid Tumor 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Advanced Solid Tumors 3Urologic Neoplasms 2Treatment-Refractory Solid Tumors 2Solid Cancers 2Recurrence 2

Interventions

trifluridine tipiracil drug combination 1spartalizumab 1selinexor 1ixazomib 1futibatinib 1fludarabine 1atezolizumab 1TAS-116 1Ramucirumab 1Ifosfamide 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Alveolar Soft Part × atezolizumab × Clear all
NCT06066138 2026-06-04

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
30 enrolled
DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡